Rhumbline Advisers Raises Stake in Keros Therapeutics, Inc. $KROS

Rhumbline Advisers raised its stake in Keros Therapeutics, Inc. (NASDAQ:KROS) by 9.3% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 44,669 shares of the company’s stock after buying an additional 3,802 shares during the quarter. Rhumbline Advisers’ holdings in Keros Therapeutics were worth $455,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in shares of Keros Therapeutics by 31.1% in the 1st quarter. Vanguard Group Inc. now owns 2,566,321 shares of the company’s stock valued at $26,151,000 after purchasing an additional 609,212 shares during the last quarter. ADAR1 Capital Management LLC lifted its stake in shares of Keros Therapeutics by 6,294.5% in the 1st quarter. ADAR1 Capital Management LLC now owns 1,486,461 shares of the company’s stock valued at $15,147,000 after purchasing an additional 1,463,215 shares during the last quarter. Federated Hermes Inc. lifted its stake in shares of Keros Therapeutics by 882.3% in the 1st quarter. Federated Hermes Inc. now owns 1,224,139 shares of the company’s stock valued at $12,474,000 after purchasing an additional 1,099,519 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Keros Therapeutics by 38.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 740,606 shares of the company’s stock valued at $7,547,000 after purchasing an additional 205,022 shares during the last quarter. Finally, DRW Securities LLC acquired a new position in shares of Keros Therapeutics in the 1st quarter valued at $4,737,000. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms recently issued reports on KROS. Bank of America lowered Keros Therapeutics from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $32.00 to $18.00 in a research note on Tuesday, June 10th. HC Wainwright decreased their target price on Keros Therapeutics from $25.00 to $20.00 and set a “buy” rating on the stock in a research note on Friday, August 8th. Finally, Wedbush reissued a “neutral” rating and set a $15.00 target price on shares of Keros Therapeutics in a research note on Friday, May 30th. Seven research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $30.00.

Keros Therapeutics Price Performance

KROS opened at $15.69 on Wednesday. The business has a 50 day simple moving average of $14.84 and a 200-day simple moving average of $13.71. The stock has a market capitalization of $637.33 million, a P/E ratio of 50.61, a P/E/G ratio of 2.05 and a beta of 1.06. Keros Therapeutics, Inc. has a 12 month low of $9.12 and a 12 month high of $72.37.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.76) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.14) by $0.38. The firm had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $3.83 million. Keros Therapeutics had a return on equity of 2.96% and a net margin of 8.06%.Keros Therapeutics’s revenue was up 49002.7% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.25) earnings per share. Research analysts anticipate that Keros Therapeutics, Inc. will post -4.74 EPS for the current year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.